RECENT PUBLICATIONS (Last 5 years)

1. Glucose-Lowering Medications and Risk of Chronic Obstructive Pulmonary Disease Exacerbations in Patients with Type 2 Diabetes JAMA Intern Med. -2025
2. Comparative Effectiveness of Individual Sodium-Glucose Cotransporter 2 Inhibitors JAMA Intern Med. -2025
3. Empagliflozin and the Risk of Retinopathy in Patients With Type 2 Diabetes JAMA Ophthalmol. -2024
4. Glucagon-like peptide-1 receptor agonists before upper gastrointestinal endoscopy and risk of pulmonary aspiration or discontinuation of procedure: cohort study BMJ. - 2024
5. SGLT-2 inhibitors, GLP-1 receptor agonists, and DPP-4 inhibitors and risk of hyperkalemia among people with type 2 diabetes in clinical practice: population based cohort study​ BMJ. - 2024
6. Health Care Utilization and Costs Associated With Empagliflozin in Older Adults With Type 2 Diabetes Diabetes Care. -2024
7. Empagliflozin and Risk of Incident Gout: Analysis from the EMPagliflozin Comparative Effectiveness and SafEty (EMPRISE) Cohort Study J Gen Intern Med. -2024
8. ​Effectiveness and safety of empagliflozin: final results from the EMPRISE study Diabetologia. -2024
9. Cardiorenal effectiveness of empagliflozin vs. glucagon-like peptide-1 receptor agonists: final-year results from the EMPRISE study Cardiovasc Diabetol. -2024
10. Sodium-Glucose Cotransporter 2 Inhibitors and Nephrolithiasis Risk in Patients with Type 2 Diabetes JAMA Intern Med. -2024
11. High-Dose vs. Standard-Dose Influenza Vaccine and Cardiopulmonary Hospitalization or Mortality: Emulating the INVESTED Trial Using Insurance Claims Data Clin Pharmacol Ther. -2024
12. A population-based cohort defined risk of hyperkalemia after initiating SGLT-2 inhibitors, GLP1 receptor agonists or DPP-4 inhibitors to patients with chronic kidney disease and type 2 diabetes Kidney Int. - 2023
13. Risk of severe hypoglycemia with newer second-line glucose-lowering medications in older adults with type 2 diabetes stratified by known indicators of hypoglycemia risk J Gerontol A Biol Sci Med Sci. - 2023 
14. Achieving comparability in glycemic control between antidiabetic treatment strategies in pregnancy when using real world data Pharmacoepidemiol Drug Saf. - 2023
15. Successful implementation of a stakeholder engagement program for pharmacoepidemiologic research Pharmacoepidemiol Drug Saf. - 2023
16. ​Comparative Cardiovascular Effectiveness and Safety of SGLT-2 Inhibitors, GLP-1 Receptor Agonists, and DPP-4 Inhibitors According to Frailty in Type 2 Diabetes  Diabetes Care. - 2023
17. Stratified analysis in comparative effectiveness studies that emulate randomized trials​ Pharmacoepidemiol Drug Saf. - 2023
18. Contemporary trends in the utilization of second-line pharmacological therapies for type 2 diabetes in the United States and the United Kingdom Diabetes Obes Metab. - 2023 
19. Antidiabetes medication initiation trends in US adults with cirrhosis and type 2 diabetes: A nationwide study​ Diabetes Obes Metab. - 2023
20. Safety of SGLT2i with regard to bone and mineral metabolism in patients with CKD Curr Opin Nephrol Hypertens. - 2023
21. Continuous Glucose Monitoring in Adults with Diabetes in Clinical Practice: Increased Access and Education Needed  J Gen Intern Med. - 2023
22. Comparing Effectiveness and Safety of SGLT2 Inhibitors vs DPP-4 Inhibitors in Patients With Type 2 Diabetes and Varying Baseline HbA1c Levels JAMA Intern Med. - 2023 
23. Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with CKD and Type 2 Diabetes: Population-Based US Cohort Study Clin J Am Soc Nephrol - 2023 
24. Deficits and Disparities in Early Uptake of Glucagon-Like Peptide 1 Receptor Agonists and SGLT2i Among Medicare-Insured Adults Following a New Diagnosis of Cardiovascular Disease or Heart Failure Diabetes Care. - 2023​
25. Sodium-Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease Ann Intern Med. - 2022 
26. The use of glucose-lowering medications for the treatment of type 2 diabetes mellitus during pregnancy in the United States Endocrinol Diabetes Metab - 2022 
27. Effectiveness and safety of empagliflozin in routine care patients: Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study: Diabetes Obes Metab. - 2022
28. Evolving channeling in prescribing SGLT-2 inhibitors as first-line treatment for type 2 diabetes: Pharmacoepidemiol Drug Saf. - 2022​
29. Prevalence of Avoidable and Bias-Inflicting Methodological Pitfalls in Real-World Studies of Medication Safety and Effectiveness: Clin Pharmacol Ther. -2022
30. Glucagon-Like Peptide-1 Receptor Agonists and Hepatic Decompensation Events in Patients With Cirrhosis and Diabetes: Clin Gastroenterol Hepatol. - 2022
31. SGLT2 Inhibitors and the Risk of Acute Kidney Injury in Older Adults With Type 2 Diabetes: Am J Kidney Dis. - 2022
32. Accuracy of identifying diagnosis of moderate to severe chronic kidney disease in administrative claims data: Pharmacoepidemiol Drug Saf. - 2022
33. Medication Optimization for New Initiators of Empagliflozin for Diabetic Kidney Disease: Clin Diabetes. - 2022
34. Risk of Hospitalization for Heart Failure in Patients With Hyperkalemia Treated With Sodium Zirconium Cyclosilicate Versus Patiromer: J Card Fail. - 2022
35. Three Sides to the Story: Adherence Trajectories During the First Year of SGLT2 Inhibitor Therapy Among Medicare Beneficiaries: Diabetes Care. - 2022
36. Cardiovascular Outcomes in Patients Initiating First-Line Treatment of Type 2 Diabetes With Sodium-Glucose Cotransporter-2 Inhibitors Versus Metformin : A Cohort Study: Ann Intern Med. - 2022​
37. Evolving channeling in prescribing SGLT-2 inhibitors as first-line treatment for type 2 diabetes: Pharmacoepidemiol Drug Saf. - 2022
38. Association of Sodium-Glucose Cotransporter-2 Inhibitors With Fracture Risk in Older Adults With Type 2 Diabetes: JAMA Netw Open - 2021
39. Prescribing Trends of Antidiabetes Medications in Patients With Type 2 Diabetes and Diabetic Kidney Disease, a Cohort Study: Diabetes Care. - 2021
40. Sodium-Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease: Ann Intern Med. - 2021
41. Comparative Effectiveness and Safety of Sodium-Glucose Cotransporter 2 Inhibitors Versus Glucagon-Like Peptide 1 Receptor Agonists in Older Adults: Diabetes Care. - 2021
42. Conducting Real-world Evidence Studies on the Clinical Outcomes of Diabetes Treatments: Endocr Rev. - 2021
43. Risk of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Addition of SGLT2 Inhibitors Versus Sulfonylureas to Baseline GLP-1RA Therapy:  Circulation. -2021 
44. Validation of obesity-related diagnosis codes in claims data: Diabetes Obes Metab.​ - 2021
45. The modifying effects of adiposity on the cardiovascular safety of sulphonylureas: Diabetes Obes Metab. - 2021
46. Prescribing trends and clinical characteristics of patients starting antiobesity drugs in the United States: Diabetes Obes Metab.​ - 2021
47. How well can we assess the validity of non-randomised studies of medications? A systematic review of assessment tools: BMJ Open. - 2021
48. Trends in First-Line Glucose-Lowering Drug Use in Adults With Type 2 Diabetes in Light of Emerging Evidence for SGLT-2i and GLP-1RA: Diabetes Care. - 2021
49. Risk of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Addition of SGLT2 Inhibitors Versus Sulfonylureas to Baseline GLP-1RA Therapy: Circulation. - 2021
50. A novel data mining application to detect safety signals for newly approved medications in routine care of patients with diabetes: Endocrinol Diabetes Metab.​ - 2021
51. Sodium-Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease: Ann Intern Med.​ - 2021
52. Comparative effectiveness of empagliflozin in reducing total cardiovascular events in the empagliflozin comparative effectiveness and safety (EMPRISE) study: Journal of the American College of Cardiology - 2021
53. Decision Algorithm for Prescribing SGLT2 Inhibitors and GLP-1 Receptor Agonists for Diabetic Kidney Disease: Clin J Am Soc Nephrol​ -2020
54. Assessing the Risk for Gout With Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes: A Population-Based Cohort Study: Ann Intern Med. - 2020
55. Trends in Clinical Characteristics and Prescribing Preferences for SGLT2 Inhibitors and GLP-1 Receptor Agonists, 2013-2018: Diabetes Care. - 2020
56. Heterogeneity of antidiabetic treatment effect on the risk of major adverse cardiovascular events in type 2 diabetes: a systematic review and meta-analysis: Cardiovascular Diabetology. - 2020
57. Evaluation of Risk of Bullous Pemphigoid With Initiation of Dipeptidyl Peptidase-4 Inhibitor vs Second-generation Sulfonylurea: JAMA Dermatol. - 2020
58. Risk of amputation with canagliflozin across categories of age and cardiovascular risk in three US nationwide databases: cohort study: BMJ. - 2020
59. Using Data From Routine Care to Estimate the Effectiveness and Potential Limitations of Outcomes-Based Contracts for Diabetes Medications: Value Health. - 2020
60. Transparency in real-world evidence (RWE) studies to build confidence for decision-making: Reporting RWE research in diabetes: Diabetes Obes Metab. - 2020
61. The EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study programme: Design and exposure accrual for an evaluation of empagliflozin in routine clinical care: Endocrinol Diabetes Metab. - 2019
62. Glucose-lowering medications and the risk of cancer: A methodological review of studies based on real-world data: Diabetes Obes Metab. - 2019
63. Sodium-Glucose Cotransporter-2 Inhibitors and the Risk for Severe Urinary Tract Infections: A Population-Based Cohort Study: Ann Intern Med. - 2019
64. Sodium-glucose cotransporter 2 inhibitors for diabetic kidney disease: a primer for deprescribing: Clin Kidney J. - 2019
65. Cardiovascular safety of linagliptin compared with other oral glucose-lowering agents in patients with type 2 diabetes: A sequential monitoring programme in routine care: Diabetes Obes Metab. - 2019
66. Empagliflozin and the Risk of Heart Failure Hospitalization in Routine Clinical Care: Circulation.​ - 2019
67. Fracture Risk After Initiation of Use of Canagliflozin: A Cohort Study: Ann Intern Med. - 2019
68. Comparative risk of genital infections associated with sodium-glucose co-transporter-2 inhibitors: Diabetes Obes Metab. 2019

​

Division of Pharmacoepidemiology & Pharmacoeconomics
Department of Medicine
Brigham & Women's Hospital and Harvard Medical School
1620 Tremont Street Suite 3030 Boston, MA 02120